Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1425 of 5804
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of ZEN003694 when given together with abemaciclib in treating patients with NUT carcinoma, breast cancer or other solid tumors that have spread from where it first started (primary site) to other places in the body …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough prostate cancer: first human trial of VIR-5500 begins
Disease control Recruiting nowThe study will be conducted in 4 parts and will commence with dose escalation of VIR-5500 as a monotherapy (Part 1), followed by combination escalation (Part 3a), monotherapy dose expansion (Part 2) and combination dose expansion (Part 4a). * Part 1 (Monotherapy Dose Escalation)…
Phase: PHASE1 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThe purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Spinal cord injury drug trial halted early
Disease control CompletedA Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects
Phase: PHASE1, PHASE2 • Sponsor: NervGen Pharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New lifestyle program aims to tame type 2 diabetes with less medication
Disease control Recruiting nowA Randomized Control Trial (RCT) with 1:1 randomization of adults newly diagnosed with type 2 diabetes (T2D) to Routine Care (RC) and RC + Glycemic Excursion Minimization (RC+GEM); a program that provides RC in addition to continuous glucose monitors (CGM) within a structured, se…
Phase: NA • Sponsor: Chiara Fabris, PhD • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug shows promise for slowing liver damage in rare genetic disease
Disease control OngoingThe main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-alpha-1 antitrypsin (Z-AAT) protein. People who have taken part in previous fazirsiran studies (AROAAT2001 \[NCT03945292\] or AROAAT2002 \[NCT03…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Radioactive microspheres show promise in early liver cancer trial
Disease control CompletedThe goal of this clinical trial is to evaluate the safety and efficacy of NRT6003 Injection in patients with unresectable HCC.
Phase: PHASE1 • Sponsor: Chengdu New Radiomedicine Technology Co. LTD. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New Short-Course malaria treatment could prevent relapses
Disease control CompletedSignificant gains have been made in reducing the overall burden of malaria worldwide, however these have been far greater for Plasmodium falciparum than P. vivax. P. vivax remains a major obstacle to malaria control and elimination efforts, largely due to its ability to form dor…
Phase: NA • Sponsor: Macfarlane Burnet Institute for Medical Research and Public Health Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Smart supplement strategy could save babies in ethiopia
Prevention OngoingThe goal of this randomized effectiveness study is to evaluate the different targeting strategies for the delivery of balanced energy and protein (BEP) supplements among pregnant women in Addis Ababa, Ethiopia. The main goals of the study are to: 1) determine the effectiveness of…
Phase: NA • Sponsor: Harvard School of Public Health (HSPH) • Aim: Prevention
Last updated Jul 09, 2026 00:00 UTC
-
New hope for PBC: experimental drug CS0159 enters Mid-Stage trial
Disease control OngoingA phase II study to evaluate safety, tolerability and efficacy of CS0159 in patients with PBC (Primary Biliary Cholangitis).
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Simple antibiotic pill may protect mothers and babies during induced labor
Disease control Recruiting nowThis is a double blinded randomized control trial involving administration of 2 grams prophylactic azithromycin in third trimester patients undergoing induction of labor at our institution to demonstrate reduction in maternal and neonatal infection.
Phase: PHASE1 • Sponsor: Arrowhead Regional Medical Center • Aim: Disease control
Last updated Jun 26, 2026 16:13 UTC
-
Short therapy shows promise for Kids' nightmares and suicide risk
Symptom relief CompletedThe goal of this clinical trial is to assess the efficacy of CBT-NC intervention to determine its impact on mental health and suicidality in children ages 6-17. The main aims are: Aim 1: Examine CBT-NC efficacy for improving nightmare distress and frequency in youth with chronic…
Phase: NA • Sponsor: University of Oklahoma • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
AI tool aims to end guesswork in depression treatment
Knowledge-focused OngoingOPADE is a non-profit, observational, multicenter, open-label study aimed at defining personalized treatment for Major Depressive Disorder (MDD). In particular, we will combine genetics, epigenetics, microbiome, immune response data together with anamnesis, questionnaires, electr…
Sponsor: Alessio Fasano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Tighter blood pressure control may reduce brain aneurysm risk
Disease control CompletedThe goal of this randomized controlled trial is to evaluate the benefits and safety of controlled hypotension in Chinese patients with unruptured intracranial aneurysms(UIA). The main questions it aims to answer are: * To provide high-level evidence of the benefits and safety o…
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Mushroom compound targets kidney cancer in dialysis patients
Disease control Recruiting nowA phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy. All participants must have end-stage kidney disease and be receiving stable…
Phase: PHASE1, PHASE2 • Sponsor: Oncorena AB • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Brain-Training exercise games aim to stop Parkinson's falls
Symptom relief Recruiting nowPeople living with Parkinson's (PwP) rank balance problems amongst the most disabling symptom. Over time, balance function continues to decline and PwP go on to fall, affecting between 45-68% of PwP. Falling directly impacts upon the individuals' quality of life (QoL), as it prev…
Phase: NA • Sponsor: University of Leicester • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Could a vaccine tame chronic hepatitis b?
Disease control OngoingThe goal of this clinical trial is to test ISA104 in patients with chronic hepatitis B. The main question\[s\] it aims to answer are: * How safe is ISA104? * Does ISA104 induce immunity against hepatitis B virus? Different doses of the vaccine ISA104 will be administered to par…
Phase: PHASE1, PHASE2 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a diabetes drug help heart failure patients shed excess fluid?
Disease control OngoingThis is a 60-patient randomized, double-blind, placebo-controlled mechanistic study to understand the utility of empagliflozin in worsening heart failure (HF) patients with or without diabetes. Participants will be randomized to empagliflozin or placebo for 6 weeks, followed by a…
Phase: PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Cold war on baldness: which scalp cooling method wins for breast cancer patients?
Symptom relief OngoingThe prevention of chemotherapy-induced alopecia (CIA) is still imperfectly managed in France. Strengthening the evidence base on the benefits of strategies to prevent CIA, based on robust methodologies, remains a prerequisite for better integration of appropriate supportive care …
Phase: NA • Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New injection aims to tame chronic hepatitis b
Disease control CompletedThe purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy participants after single and multiple doses, and evaluate the preliminary efficacy of AHB-137 in CHB participants after up to 24 weeks of treatmen…
Phase: PHASE1, PHASE2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC